智通财经APP获悉，8月10日，乳品深加工与活性原料创新研讨会在黑龙江齐齐哈尔市举办。会议由中国食品科学技术学会组织，来自中国乳制品工业协 会、中国农业科学院、南开大学、上海交通大学、大连工业大学及中国飞鹤等机构的乳品科学、营养健康、生物科技等领域的专家代表参加了会议。与会专 家围绕乳制品深加工的最新科研进展、活性营养产业化核心技术及全链条创新实践展开深入探讨，旨在推动产学研深度融合。 作为国内乳业领军企业，中国飞鹤(06186)在会上重点分享了其"新一代鲜活营养"的研发与产业实践成果，涵盖新鲜奶源、鲜活科技、鲜活营养产品及科学 实证全链条，为行业高质量发展提供经验。 突破鲜活营养新趋势，共见行业鲜活实证 在国家政策与消费升级双重驱动下，中国乳业加速向高质量转型。与会专家一致认为，"保鲜增活"是婴配粉乃至整个乳业发展的核心命题。 中国农业科学院研究员王加启表示，鲜活营养是当前整个行业升级与产品品质提升的重要方向。保鲜增活就是最大程度的保留牛奶中的天然活性元素，使珍 贵的生物天然活性物质达到更高水平，这是整个婴配粉制造的核心，也是整个行业发展的重要方向。 实际上，破解鲜活难题需要全产业链协同创新，中国乳企正在通 ...

Core Viewpoint - The announcement from Feihe has led to a significant decline in its market value, with a projected revenue drop and net profit decrease for the first half of 2025 compared to the previous year [1][4]. Group 1: Financial Performance - Feihe expects revenue for the first half of 2025 to be approximately 9.1 billion to 9.3 billion yuan, down from 10.1 billion yuan in the same period of 2024, representing a decline of about 8% to 10% [1]. - The projected net profit for the first half of 2025 is estimated to be between 1 billion to 1.2 billion yuan, reflecting a year-on-year decrease of approximately 37% to 47% [1]. - Following the announcement, Feihe's stock price plummeted by 17.02% on the next trading day and an additional 3.17% the following day, resulting in a total market value loss of 10.15 billion HKD, equivalent to approximately 9.28 billion yuan [1]. Group 2: Market Dynamics - The decline in birth rates poses a long-term challenge for the infant formula industry, with Feihe's revenue and profit having previously increased in 2024, but now facing a downturn again in 2025 [1][16]. - Feihe has initiated a substantial fertility subsidy program valued at 1.2 billion yuan to attract potential customers, but this strategy may lead to a price war and does not guarantee revenue growth [2][3]. - Competitors such as Yili and Junlebao have also launched similar subsidy programs, which may dilute the effectiveness of Feihe's efforts to capture market share [3]. Group 3: Inventory and Growth Challenges - Feihe's inventory levels have increased significantly, with stock surpassing 2 billion yuan, and inventory turnover days rising from 80 days in 2021 to 113.7 days in 2024 [6][10]. - The management anticipates completing inventory adjustments by the third quarter of 2025, but the impact of the subsidy program on revenue may be more pronounced in the second half of the year [9][10]. - Analysts from various financial institutions have revised their growth expectations for Feihe, with projections indicating a potential revenue growth of only 0.5% for 2025, down from earlier estimates of 9% [5]. Group 4: Product Strategy and Market Trends - Feihe plans to launch higher-end products in the second half of 2025, aligning with market trends that show growth in the ultra-premium segment of the infant formula market [12][11]. - Data indicates that the ultra-high-end market has seen a year-on-year growth of 13.3% in early 2025, while other segments have experienced declines [12]. - Despite these efforts, the performance of new products remains uncertain, and the overall demand for infant formula is declining due to lower birth rates [13][16]. Group 5: Shareholder Returns - Feihe has announced a minimum share buyback plan of 1 billion yuan and a dividend distribution of no less than 2 billion yuan, aiming to enhance shareholder value [14]. - However, despite these positive initiatives, the negative impact of the company's financial performance has overshadowed these efforts, leading to a significant drop in market capitalization [15].